Literature DB >> 2510587

Patterns of plasma levels of catechols in neurogenic orthostatic hypotension.

D S Goldstein1, R J Polinsky, M Garty, D Robertson, R T Brown, I Biaggioni, R Stull, I J Kopin.   

Abstract

Patients with neurogenic orthostatic hypotension can have deficits in sympathetic neural function at any of several levels of the sympathetic neuraxis. We determined whether patterns of plasma levels of dopa, norepinephrine, dihydroxyphenylglycol, and dihydroxyphenylacetic acid would distinguish patients with orthostatic hypotension associated with multiple system atrophy, pure autonomic failure, or deficiency of dopamine-beta-hydroxylase. Plasma levels of catechols were normal in most patients with multiple system atrophy, consistent with relatively intact peripheral sympathetic neurons; in contrast, most patients with pure autonomic failure had decreased levels of all four catechols, consistent with degenerative loss of sympathetic nerve endings. Patients with deficiency of dopamine-beta-hydroxylase had increased levels of dopa and dihydroxyphenylacetic acid and markedly decreased levels of norepinephrine and dihydroxyphenylglycol, suggesting compensatory increases in sympathetic nerve activity in the absence of norepinephrine biosynthesis. Subgroups of patients with pure autonomic failure or multiple system atrophy had low levels of norepinephrine with normal levels of dopa, dihydroxyphenylglycol, and dihydroxyphenylacetic acid, consistent with normal catecholamine biosynthesis and decreased postganglionic sympathetic nerve traffic or decreased exocytotic release from sympathetic nerve endings. The results demonstrate the value of examining patterns of plasma levels of catechols to elucidate mechanisms of neurogenic orthostatic hypotension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510587     DOI: 10.1002/ana.410260410

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Pattern of plasma levels of catecholamines in familial dysautonomia.

Authors:  F B Axelrod; D S Goldstein; C Holmes; D Berlin; I J Kopin
Journal:  Clin Auton Res       Date:  1996-08       Impact factor: 4.435

2.  Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure.

Authors:  Alfredo Gamboa; Cyndya Shibao; André Diedrich; Sachin Y Paranjape; Ginnie Farley; Brian Christman; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2008-04-21       Impact factor: 10.190

Review 3.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

4.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

5.  Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome.

Authors:  D S Goldstein; A McRae; C Holmes; M C Dalakas
Journal:  Clin Auton Res       Date:  1996-02       Impact factor: 4.435

6.  Multiple system atrophy: using clinical pharmacology to reveal pathophysiology.

Authors:  Jens Jordan; Cyndya Shibao; Italo Biaggioni
Journal:  Clin Auton Res       Date:  2015-03-11       Impact factor: 4.435

Review 7.  Pharmacotherapy of autonomic failure.

Authors:  Cyndya Shibao; Luis Okamoto; Italo Biaggioni
Journal:  Pharmacol Ther       Date:  2011-06-12       Impact factor: 12.310

8.  Effect of neurovestibular stimulation on autonomic regulation.

Authors:  F Costa; P Lavin; D Robertson; I Biaggioni
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

9.  Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.

Authors:  David S Goldstein; Courtney Holmes; Horacio Kaufmann; Roy Freeman
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

10.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.